36% of readmissions at 7 days could be prevented

More than one-third of readmissions within seven days of discharge—36 percent—are preventable, according to research published May 1 in the Annals of Internal Medicine.

A healthcare organization experiencing frequent readmissions may be providing lower quality care, but there are many factors that can lead to readmission. In this study, researchers examined different American medical centers to identify what made readmissions within seven days of discharge different from those between eight and 30 days.

A total of 10 academic medical centers in the U.S., with 822 adults readmitted to a general medicine service, were evaluated. For each readmission, two physicians conducted a survey to identify if it was preventable.

 

Results showed 36.2 percent of early readmission and 23 percent of all readmissions were preventable. Hospitals were more able to prevent early readmissions, while outpatient clinics and home care services were more adept in preventing later readmissions.

“Early readmissions were more likely to be preventable and amenable to hospital-based interventions,” concluded first author Kelly Graham, MD, MPH, and colleagues. “Late readmissions were less likely to be preventable and were more amenable to ambulatory and home-based interventions.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.